Incorporating the oncotype DX breast cancer assay into community pratice: An expert Q&A and case study sampling

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 2 SUPPL. 3, 2008, Pages

  Mamounas, Eleftherios P ^a,b   Budd, G Thomas ^c   Miller, Kathy D ^d,e  

^a Northeastern Ohio Medical University   (United States)

^b Aultman Cancer Center   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AURORA A KINASE; CATHEPSIN V; CD68 ANTIGEN; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE M1; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STROMELYSIN 3; SURVIVIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY CARE; COMPUTER PROGRAM; DRUG CHOICE; GENE EXPRESSION PROFILING; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MONOTHERAPY; ONLINE SYSTEM; PATIENT CARE; PHARMACOGENETICS; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT PLANNING; VALIDATION STUDY;

EID: 41649104667     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol. 2007;19:547-551.
2. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35-42.
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
4. Cobleigh MA, Tabesh B, Bitterman P., et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11 (24 pt 1):8623-8631.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000:406(6797):747-752.
6. Golub TR, Slonim DK, Tamayo P. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286(5439):531-537.
7. van't Veer LJ, Dai H, vast de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003;5(1):57-58.
8. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk ofbreast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.
9. Paik S, Tang G, Shak S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
10. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347-350.
11. Albain K, Barlow W, Shak S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). Presentation at the 30th Annual San Antonio Breast Cancer Sym-posium; San Antonio, TX; December 13-16, 2007. Abstract 10.
12. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27:137-142.
13. Goldstein L, Ravdin P Gray R, et al. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. Presentation at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007. Abstract 63.
14. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
15. Clinical practice guidelines in Oncology. National Comprehensive Cancer Network. http://www.nccn.org/.
16. Lillie SE, Brewer NT, O'Neill SC, et al. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy: Cancer Epidemiol Biomarkers Prev. 2007; 16:249-255.
17. Mumby PB, Lo SS, Norton J, et al. Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Presentation at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007. Abstract 1092.
18. Liang H, Brufsky AM, Lembersky BB, et al. A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Presentation at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007. Abstract 2061.
19. Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negadve, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania. Presentation at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007. Abstract 3082.
20. Lyman GH, Cosler LE, Kuderet NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer in economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109:1011-1018.
21. Badve SS, Baehner FL, Gray R, et al. ER and PR assessment in ECOG 2197: comparison of locally determined IHG with centrally determined IHC and quantitative RT-PCR. Presentation at the 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7-8. 2007. Abstract 87.
22. Baehner FL, Maddala T, Alexander C, et al. A Kaiser-Permanente population-based study of ER and PR expression by the standard method, immunohistochemistry (IHC), compared to a new method, quantitative reverse transcription polymerase chain reaction (RT-PCR). Presentation at the 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7-8, 2007. Abstract 88.